Izalontamab Brengitecan Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study 5h
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 23 October
